 |
 |

Detection of Prostate and Colon Cancer
Scott Stern, MD;
Diane Altkorn, MD;
Wendy Levinson, MD
JAMA. 1998;280:117-118.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
INTRODUCTION
CANCER DETECTION continues to be an important focus of primary care. Many groups, including the American Cancer Society and the US Preventive Services Task Force, periodically publish recommendations for cancer screening. As new information becomes available, these recommendations need reevaluation and revision. In this article, we review recent studies that have modified our approach to the detection of prostate cancer and colorectal cancer.
Prostate Cancer
Screening for prostate cancer by serum prostate-specific antigen (PSA) measurement continues to generate controversy. PSA testing is recommended by the American Cancer Society1 but not by the US Preventive Services Task Force.2 Critics of PSA screening raise several concerns. First, there have been no randomized trials showing that the detection of prostate cancer by PSA screening decreases prostate cancerassociated morbidity or mortality. Second, autopsy studies suggest that 30% of men have indolent tumors that develop late in life . . . [Full Text of this Article]
Colon Cancer
From the Department of Medicine, University of Chicago, Chicago, Ill.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Talking With Patients About Screening for Prostate Cancer
Rosenthal et al.
JAMA 1999;281:133-133.
FULL TEXT
|